Metraipolis › archive › dc_28842e975973

CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them? — Europe PMC PMID:41226361

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41226361
DOI
10.3390/ijms262110322
License (as archived)
solo-consultazione
Archived
2026-11-09T02:58:49.932Z
SHA-256 of the archived text
450b6a1a194e1aa5435f623ec71af78eb42c11788059e7524d582d1e53628eec
Stable URL of this page
https://metraipolis.com/documento/dc_28842e975973

How to cite

CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them? — Europe PMC PMID:41226361 — Europe PMC (en), https://europepmc.org/article/MED/41226361 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_28842e975973 (Metraipolis archive dc_28842e975973, sha256 450b6a1a194e1aa5435f623ec71af78eb42c11788059e7524d582d1e53628eec)
BibTeX
@misc{dc28842e975973,
  title = {CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them? — Europe PMC PMID:41226361},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41226361},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_28842e975973; sha256 450b6a1a194e1aa5435f623ec71af78eb42c11788059e7524d582d1e53628eec},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41226361. Agents can read the archived copy with the MCP tool read_document.